Skip to content
Evigrade
CriticalAntiretroviral, HIV protease inhibitor×Atypical antipsychotics

Updated · Methodology

Mechanism

CYP3A4 is the main enzyme that metabolises quetiapine (quetiapine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Atazanavir inhibits this enzyme, so quetiapine levels are expected to rise (atazanavir SmPC, European Medicines Agency, EMA). Atazanavir is taken with ritonavir, which inhibits CYP3A4 more strongly than atazanavir itself (EMA). Ketoconazole, another CYP3A4 inhibitor, increased the quetiapine area under the concentration curve (AUC) 5- to 8-fold (quetiapine SmPC, AEMPS). The documents give no figures for atazanavir.

Symptoms

Higher quetiapine levels can lead to coma (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). In quetiapine overdose, somnolence and sedation, tachycardia, hypotension and anticholinergic effects have been reported, as well as QT prolongation, seizures, respiratory depression, urinary retention, confusion, delirium, coma and death (quetiapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Post-marketing reports also describe QT prolongation with quetiapine at therapeutic doses (AEMPS), and atazanavir causes dose-related asymptomatic PR prolongation (EMA). QT and PR prolongation show only on an electrocardiogram (ECG).

Management

The combination is contraindicated. The atazanavir summary of product characteristics (SmPC) lists quetiapine among contraindicated drugs (atazanavir SmPC, European Medicines Agency, EMA), and so does the atazanavir/cobicistat SmPC (EMA). The quetiapine SmPC contraindicates CYP3A4 inhibitors, including human immunodeficiency virus (HIV) protease inhibitors (quetiapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraindication in the atazanavir SmPC does not depend on the regimen. The recommended adult regimen is atazanavir 300 mg with ritonavir 100 mg once daily with food (EMA). The US atazanavir label is less strict. If atazanavir with ritonavir is started in a patient already taking quetiapine, the label advises considering an alternative antiretroviral regimen. If the combination cannot be avoided, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine adverse reactions (atazanavir label, US Food and Drug Administration, FDA). The European SmPCs do not include this option. Use quetiapine with caution together with drugs that prolong the QT interval, especially in older people and in patients with congenital long QT syndrome, congestive heart failure, cardiac hypertrophy, hypokalaemia or hypomagnesaemia (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Quetiapine